ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype
Abstract
Neuroendocrine phenotype is commonly associated with therapy resistance and poor prognoses in small-cell neuroendocrine cancers (SCNCs), such as neuroendocrine prostate cancer (NEPC) and small-cell lung cancer (SCLC). Expression levels of current neuroendocrine markers exhibit high case-by-case variability, so multiple markers are used in combination to identify SCNCs. Here, we report that ACAA2 is elevated in SCNCs and is a potential molecular indicator for SCNCs.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 05, 2023
- Source ID
- 10.1038/s41416-023-02448-y
Entities
People
- Alifiani B. Hartono
- Angus Toland
- Busola R. Alabi
- Chanjuan Shi
- Conner J. Sessions
- En-Chi Hsu
- Eva Corey
- Holly M. Nguyen
- James D Brooks
- Jiaoti Huang
- Merve Aslan
- Michelle Shen
- Rosalie Nolley
- Shiqin Liu
- Tanya Stoyanova
Organizations
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense
- United States Department of Health and Human Services